NCT07172919 2026-04-09A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationAmgenPhase 2 Recruiting14 enrolled
NCT00891930 2024-07-17Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabNantBioScience, Inc.Phase 2 Completed74 enrolled 15 charts
NCT01776307 2023-11-15A Study of BBI608 in Adult Patients With Advanced Colorectal CancerSumitomo Pharma America, Inc.Phase 2 Completed200 enrolled 23 charts
NCT04169347 2023-07-27FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal CancerCriterium, Inc.Phase 2 Unknown27 enrolled
NCT00819780 2022-12-06PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsAmgenPhase 2 Completed285 enrolled 31 charts
NCT00089635 2022-11-07Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal CancerAmgenPhase 2 Completed203 enrolled 14 charts
NCT00446446 2022-10-05PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)AmgenPhase 2 Completed52 enrolled 17 charts
NCT02448810 2021-05-25Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal CancerTakedaPhase 2 Terminated115 enrolled 22 charts
NCT00508404 2019-11-19Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerAmgenPhase 2 Completed154 enrolled 18 charts
NCT00756444 2018-11-15A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckAmgenPhase 2 Completed67 enrolled 8 charts
NCT00418938 2018-10-17SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialAmgenPhase 2 Completed266 enrolled 17 charts
NCT00454779 2018-10-17PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of ResponseAmgenPhase 2 Completed113 enrolled 18 charts
NCT00500760 2018-10-17Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck CancerAmgenPhase 2 Completed153 enrolled 18 charts
NCT00547157 2017-03-15Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and NeckAmgenPhase 2 Completed152 enrolled 18 charts
NCT00083616 2014-01-10Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin ChemotherapyAmgenPhase 2 Completed185 enrolled 15 charts
NCT00111761 2013-12-12Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal CancerAmgenPhase 2 Completed43 enrolled 20 charts
NCT00111774 2013-05-14Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinomaAmgenPhase 2 Completed150 enrolled
NCT00425035 2013-05-13Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2AmgenPhase 2 Completed115 enrolled
NCT00113776 2011-01-21Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal CancerAmgenPhase 2 Completed
NCT00101920 2010-10-15ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)AmgenPhase 2 Completed50 enrolled
NCT00327119 2009-09-14Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal CancerAmgenPhase 2 Completed50 enrolled
NCT00425204 2008-09-15Study for Patients Who Have Benefited and Tolerated Prior Panitumumab TreatmentAmgenPhase 2 Completed31 enrolled
NCT00034346 2007-12-24ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)AmgenPhase 2 Completed194 enrolled
NCT00061126 2005-06-24ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the BodyAbgenixPhase 2 Completed50 enrolled